Abstracts tagged "canakinumab and corticosteroids"

Abstract Number: 2865 • 2018 ACR/ARHP Annual Meeting
Canakinumab, on a Reduced Dose or a Prolonged Dose Interval without Concomitant Corticosteroids and Methotrexate, Maintains Efficacy in Systemic Juvenile Idiopathic Arthritis Patients in Clinical Remission
Pierre Quartier¹, Ekaterina Alexeeva², Carine Wouters³, Inmaculada Calvo⁴, Tilmann Kallinich⁵, Bo Magnusson⁶, Nico Wulffraat⁷, Xiaoling Wei⁸, Alan Slade⁹, Ken Abrams⁹ and Alberto Martini¹⁰, ¹AP-HP, Institut des Maladies Génétiques (IMAGINE), and Université Paris-Descartes, Necker-Enfants Malades Hospital, Paris, France, ²National Medical Research Center of Children's Health and Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russian Federation, ³Gasthuisberg University Hospital, Leuven, Belgium, ⁴Hospital Universitario La Fe, Valencia, Spain, ⁵Charité Berlin Campus Virchow, Berlin, Germany, ⁶Karolinska University Hospital, Stockholm, Sweden, ⁷University Medical Center Utrecht, Utrecht, Netherlands, ⁸China Novartis Institutes for Biomedical Research Co., Ltd, Beijing, China, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Universita di Genova Pediatria II, Genova, Italy
Background/Purpose: Treatment with canakinumab (CAN), a selective, human anti-IL-1β monoclonal antibody, has shown sustained therapeutic effect along with corticosteroid dose reduction/discontinuation in patients with systemic…
Abstract Number: 271 • 2013 ACR/ARHP Annual Meeting
Baseline Characteristics Of Patients With Active Systemic JIA On Canakinumab Therapy Successfully Discontinuing Corticosteroids: Secondary Analyses From A Pivotal PHASE 3 Study
Hermine Brunner¹, Nicolino Ruperto², Tamás Constantin³, Nico Wulffraat^2,4, Gerd Horneff⁴, Jordi Anton², Reinhard Berner², Fabrizia Corona⁵, Rubén J. Cuttica⁶, Marine Desjonqueres², Michel Fischbach², Maria Alessio², Alice Chieng², Wolfgang Emminger², Elie Haddad⁷, Karine Lheritier⁸, Ken Abrams⁹, Josef Hruska⁸, Daniel J. Lovell⁷ and Alberto Martini², ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology International Trials Organization (PRINTO)-Istituto Gaslini, Genova, Italy, ³Pediatric Rheumatology, University Childrens Hospital, Budapest, Hungary, ⁴PRINTO, Genoa, Italy, ⁵PRINTO-Istituto Gaslini, Genova, Italy, ⁶Hospital de Niños Pedro de Elizalde - University of Buenos Aires, Buenes Aires, Argentina, ⁷Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Interleukin-1β (IL-1β) is a key cytokine in the pathogenesis of systemic juvenile idiopathic arthritis (SJIA). Canakinumab (CAN), a selective fully human anti-IL-1β monoclonal antibody,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].